Alternative Therapies for Depression & Anxiety

For behavioral health providers facing rising demand and constrained resources, "alternative" therapies are best framed not as replacements for evidence-based conventional treatments, but as complementary and integrative options embedded within stepped-care pathways. Stepped care conceptualizes treatment intensity as dynamic: begin with low-risk, scalable options; escalate if response is inadequate; and maintain gains with sustainable practices tailored to clients' contexts (e.g., home-based activity, community classes, digital groups). Within this framework, modalities such as structured exercise, mindfulness-based cognitive therapy (MBCT), yoga, and select microbiome-targeted approaches show clinically meaningful effects and can be delivered alongside psychotherapy and medications to improve reach and acceptability. Recent high-quality syntheses underscore this positioning. For example, a 2024 network meta-analysis of 218 randomized trials (14,170 participants) found exercise efficacious for major depression, with walking/jogging, yoga, and strength training among the most effective, and yoga and strength among the most acceptable modalities compared with other treatments (i.e., fewer dropouts/adverse-event discontinuations) (Noetel et al., 2024). These forms of exercise "could be considered alongside psychotherapy and antidepressants as core treatments," which is quintessentially integrative rather than alternative (Noetel et al., 2024).

Similarly, for relapse prevention, a priority often neglected in acute-phase trials, an updated systematic review and network meta-analysis concluded that MBCT demonstrated a continuous preventive effect across 3–9 months, while CBT showed the longest, though not continuous, effect up to 24 months (Zhou et al., 2023). This places MBCT squarely in a preventive/maintenance niche within stepped care, complementing acute-phase pharmacotherapy or psychotherapy (Zhou et al., 2023).

Preventive targets emphasize relapse reduction and resilience. MBCT's durability signals prevention/relapse utility after remission or response, with group formats facilitating scalability and client engagement (Zhou et al., 2023). Maintenance targets prioritize sustaining gains with feasible, self-directed routines; the 2024 network meta-analysis supports exercise as a realistic maintenance backbone due to both effectiveness and acceptability, especially walking/jogging, yoga, and resistance training (Noetel et al., 2024). Acute targets focus on rapid symptom reduction with tolerable risk; here, exercise again shows moderate effects, and specific mind–body practices such as yoga demonstrate

improvements in anxiety disorders and depressive symptoms (after sensitivity analyses), broadening immediate options when clients prefer nonpharmacologic starts or augmentation (Martínez-Calderón et al., 2023; Wu et al., 2023).

Beyond psychobehavioral methods, microbiome-targeted strategies, notably probiotics, now have multiple meta-analyses showing substantial reductions in depressive symptoms and moderate reductions in anxiety, with strain-specific signals emerging. While typically adjunctive, these interventions can be positioned across phases (e.g., as maintenance for somatic-symptom clusters or as augmentation for residual symptoms) (Asad et al., 2024; Rahmannia et al., 2024).

Building an Evidence Hierarchy

Contemporary evidence grading prioritizes systematic reviews and meta-analyses (SR/MAs), particularly network meta-analyses (NMAs) that compare multiple treatments simultaneously. The exercise NMA (Noetel et al., 2024) quantifies head-to-head credibility, demonstrating not only overall benefits but modality-specific ranks and an intensity dose, response signal, useful for clinical dosing (e.g., target moderate intensity for larger effects). For prevention, the MBCT NMA provides time-anchored estimates of relapse reduction across follow-ups, informing maintenance schedules (Zhou et al., 2023).

Acceptability, often operationalized as all-cause discontinuation, is vital in real-world care. In the exercise NMA, yoga and strength training were better tolerated than several comparators, a practical edge when clinicians select entry-level options for ambivalent or deconditioned clients (Noetel et al., 2024). Mind–body formats (e.g., yoga) may also enhance perceived fit and engagement, contributing to adherence in both acute and maintenance phases (Martínez-Calderón et al., 2023; Wu et al., 2023).

Safety profiles and adverse-event monitoring must be explicit in documentation. Exercise carries low serious-adverse-event risk when screened; mind–body practices are generally safe with musculoskeletal precautions. Probiotics are usually well tolerated but should be matched by strain and dose to the studied evidence; client education on product quality and duration (e.g., 6–12 weeks before re-rating) is key (Asad et al., 2024; Rahmannia et al., 2024).

Meta-analyses commonly report standardized mean differences (SMD/Hedges g). To translate this into clinical meaning, couple SMDs with client-centered outcomes—remission, function/quality of life, sleep—and, where available, response rates to compute an NNT (number needed to treat). In practice, for acute efficacy, consider the magnitude (e.g., the exercise NMA reports moderate reductions vs. active controls) and whether trials include clinically significant response/remission thresholds (Noetel et al., 2024). From

event rates, one can compute NNT; if only SMDs are available, be cautious translating to risk differences and discuss uncertainty with clients. For acceptability, NNH (number needed to harm) can be approximated from adverse-event discontinuation differences when trials report them; when not reported, all-cause dropout is an imperfect but pragmatic proxy. For maintenance/prevention, the MBCT NMA emphasizes time-anchored relapse outcomes, clinically intuitive endpoints that align with shared decision-making around workload (home practice), access (group vs. individual), and sustainability (Zhou et al., 2023).

Because clients value improvements that extend beyond symptom scales, clinicians should routinely combine PHQ-9/GAD-7 with function/QoL (e.g., WHO-5, role functioning) and sleep indices (e.g., insomnia severity). Mind–body and activity-based interventions are particularly well suited to improving energy, sleep regularity, and social participation, outcomes often reflected indirectly in dropout and adherence patterns (Noetel et al., 2024; Martínez-Calderón et al., 2023).

Methodological Cautions

First, risk of bias remains a constraint. The 2024 exercise NMA noted only one study meeting Cochrane low-risk-of-bias criteria; confidence ratings for some modalities were "low" or "very low," despite consistent point estimates (Noetel et al., 2024). This underscores the need to integrate plausibility (mechanisms, converging evidence), replication, and safety when forming recommendations. Second, heterogeneity (e.g., intensity, supervision, group vs. individual delivery) complicates dose-finding; still, emerging dose–response curves for intensity support titrating toward moderate-to-vigorous targets as tolerated (Noetel et al., 2024). Third, publication bias and non-blinding (often unavoidable in behavioral trials) can inflate estimates; counter this by emphasizing acceptability, durability, and replicable protocols (Zhou et al., 2023; Noetel et al., 2024).

Given variability in trial quality and the frequent absence of head-to-head superiority over guideline-concordant treatments, clinicians should document nonpharmacologic recommendations as adjunctive by default (e.g., "Add supervised group yoga twice weekly for 8 weeks to ongoing CBT," or "Initiate home-based brisk walking 30–45 minutes three times weekly while continuing SSRI"). This approach aligns with the integrative stance from recent syntheses: the exercise NMA explicitly recommends considering exercise alongside psychotherapy and antidepressants as core treatment, not as a replacement (Noetel et al., 2024). For prevention/maintenance, clinicians can document MBCT as a relapse-prevention strategy following response, noting its continuous effect at follow-ups (Zhou et al., 2023).

The most defensible, and client-centered, way to use "alternative" therapies for depression and anxiety is to relabel them as complementary modalities and integrate them within stepped care, guided by current evidence on efficacy, acceptability, and safety. The 2024 NMA positions exercise (especially walking/jogging, yoga, and strength) as an effective and acceptable option alongside first-line treatments, particularly useful in acute and maintenance phases. The 2023 relapse-prevention NMA supports MBCT as a durable preventive strategy. Probiotics add a developing adjunctive pathway with growing, strain-sensitive signals. Across modalities, emphasize client-valued outcomes (remission, functioning, sleep) and use NNT/NNH concepts when event-based data permit. Above all, document as adjunctive unless compelling monotherapy evidence exists, and match each recommendation to phase-specific goals, preferences, and risks—so that integrative care becomes not a sideline, but a core feature of evidence-informed practice (Noetel et al., 2024; Zhou et al., 2023; Martínez-Calderón et al., 2023; Wu et al., 2023; Asad et al., 2024; Rahmannia et al., 2024).

Exercise as Antidepressant/Anxiolytic "Medicine"

Over recent years, structured exercise has emerged from the realm of lifestyle recommendation into a bona fide adjunctive therapeutic modality for depression and anxiety. For providers, understanding the evidence base, dosage/format prescriptions, mechanisms of action, and risk/contraindication parameters is essential for integrating exercise as "medicine" into comprehensive treatment plans. It is important to examine the literature to highlight why exercise matters, how to dose and format it for depression versus anxiety, the underlying mechanisms, and key safety considerations, with the goal of enabling clinicians to operationalize a six-week activation plan for client use.

Among non-drug interventions, exercise consistently shows clinically meaningful effects for depression and anxiety across diverse populations. A recent systematic review and network meta-analysis of 218 randomized controlled trials (with more than 14,000 participants) found that exercise is an effective treatment for depression, and that among modalities, walking/jogging, yoga, and strength training were more effective than many others (Noetel et al., 2024). Specifically, the study reported moderate effect sizes and good tolerability of yoga and strength training compared with controls (Noetel et al., 2024). Another meta-analysis encompassing 27 RCTs ($n \approx 1,929$) found significant reductions in depressive symptoms (SMD = –0.53, 95% CI –0.79 to –0.28) and anxiety symptoms (SMD = –0.39, 95% CI –0.66 to –0.12) with exercise interventions; notably mind–body exercises (e.g., yoga, tai chi) produced stronger associations (SMD for depression –0.89; anxiety –0.77) (Smith et al., 2023). The evidence thus supports the positioning of exercise not simply as wellness promotion, but as a therapeutic intervention with measurable effect sizes,

which can be comparable to conventional treatments in some settings (Heissel et al., 2023). Exercise therefore deserves a place in the behavioral health toolkit as an “adjunctive medicine.”

From the client-care vantage point, several practical factors strengthen the rationale for exercise: its accessibility (walking requires minimal equipment), potential for self-management (home-based programs, tele-coaching), dual benefit for physical comorbidities (cardiovascular, metabolic) and mood, and relatively low risk profile when properly screened. Behavioral health providers should therefore view exercise as a viable option for many clients, especially those seeking low-medication or lifestyle-based adjuncts, or those with residual symptoms after primary treatments.

The current evidence supports prioritizing walking/jogging, yoga, and strength training as first-line exercise modalities for depressive symptoms (Noetel et al., 2024). A practical prescription is initial dose of 3 sessions per week, 30–45 minutes each, escalating gradually based on tolerance and adherence. A clinician might recommend home-based walking or jog intervals, a twice-weekly supervised strength-training session (or guided video), and one yoga/mind–body class or video at moderate intensity. Tele-coaching check-ins (e.g., weekly or biweekly) can support adherence, outcome monitoring (PHQ-9 or equivalent), and dose escalation after 4 weeks if needed. Evidence suggests that supervised or group formats may enhance effect size and adherence (Zhang et al., 2024). When feasible, the target may escalate to 150 minutes or more per week of moderate to vigorous exercise (which aligns with physical health recommendations) but the minimum meaningful dose is nevertheless the 30–45 minute sessions three times weekly.

Although the depression literature is more robust, exercise also demonstrates meaningful anxiolytic effects. Mind–body forms (e.g., yoga, tai chi) are especially promising (Smith et al., 2023). For anxiety, a format emphasizing graded aerobic activation combined with breathing/tempo control and behavioral activation (values-based movement) is optimal. A recommended protocol: 3 sessions/week of 30 minutes moderate aerobic (e.g., brisk walk or light jog), integrated with 5–10 minutes of conscious breathing or rhythmic tempo control (e.g., cadence walking) and a values-driven movement task (e.g., walking to meet a friend, or strength training tied to a meaningful role). After 4 weeks, assessing GAD-7 and sleep/rumination metrics guides escalation (to 4 sessions/week, 40–45 minutes) or referral. For clients with primarily hyperarousal, a gentle-intensity yoga or tai chi session might substitute one aerobic session to modulate sympathetic tone and enhance adherence.

In both depression and anxiety protocols, providers should plan for 6–8 weeks of consistent adherence before major outcome rerating, with booster or maintenance plans

beyond that (e.g., maintenance yoga or walking 2–3 times/week). Adherence trackers and home-based telecoaching enhance engagement, especially in behavioral health populations with motivation/energy challenges.

Mechanisms of Action

Several converging mechanistic pathways help explain why exercise exerts antidepressant and anxiolytic effects. First, inflammatory modulation: regular aerobic and resistance training reduce systemic inflammatory cytokines (e.g., IL-6, TNF-α) and increase anti-inflammatory mediators; elevated inflammation is implicated in depression and anxiety pathophysiology. Second, neurotrophin up-regulation: exercise increases brain-derived neurotrophic factor (BDNF) and promotes neurogenesis and synaptic plasticity, notably in hippocampal and prefrontal regions, sites implicated in mood regulation and anxiety (Heissel et al., 2023). Third, behavioral activation and improved self-efficacy: by engaging clients in predictable, valued movement, and seeing their own performance progress, exercise counteracts avoidance and rumination, enhancing mastery and mood regulation (Noetel et al., 2024). Fourth, autonomic regulation and stress response balance: aerobic and mind–body movements reduce sympathetic overactivity, enhance vagal tone, and modulate HPA-axis reactivity, which are common features of anxiety and chronic depression (Smith et al., 2023). Fifth, sleep and circadian regulation: movement helps consolidate sleep architecture, improve slow-wave sleep, and regularize circadian rhythms, all of which contribute to mood stabilization and anxiety reduction. Behavioral health providers should thus view exercise as a “whole-system” intervention, biological, psychological and behavioral.

Contraindications & Risk Management

While exercise is generally safe and low risk, behavioral health providers must incorporate screening and monitoring protocols, especially when prescribing as adjunctive “medicine.” First, cardiac and medical screening is critical in clients with cardiovascular risk, uncontrolled hypertension, recent myocardial infarction, or significant comorbidities. Even moderate exercise can unmask arrhythmias or ischemia in high-risk individuals; a referral for exercise clearance (e.g., via primary care or cardiology) is prudent when risk factors are present. Second, overtraining vigilance: higher intensities and frequent sessions without adequate recovery may provoke fatigue, injury, mood lability or increased stress response. The meta-analysis noting stronger effects with higher intensity (Noetel et al., 2024) must be balanced with individual tolerance and recovery capacity. Third, for clients with orthopedic, musculoskeletal or balance issues, ensure modality adaption (e.g., seated strength training, aquatic walking) and refer to physical therapy when appropriate. Fourth, psychological contraindications: clients with active mania, severe psychosis, or acute suicidal states may require stabilization of those primary conditions

before initiating unsupervised exercise. Fifth, clients on certain medications (e.g., beta-blockers) may have blunted heart-rate response and need perceived exertion scales (e.g., Borg RPE) instead of HR monitoring. Documentation must note risk screening, client education on safety (hydration, warm-up/cool-down, footwear), and contingencies for symptom escalation (e.g., chest pain, dizziness, mood activation).

For providers, exercise is no longer a generic "lifestyle suggestion" but a structured, evidence-based adjunctive intervention with measurable effect sizes, multiple mechanisms of action, and scalable formats suitable to depression and anxiety care. The 2024 network meta-analysis underscores the strength of modalities such as walking/jogging, yoga and strength training (Noetel et al., 2024); subsequent literature further supports meaningful anxiety reduction from mind–body movements (Smith et al., 2023). By prescribing clear dosage formats, monitoring adherence and outcomes, and attending to safety and screening, clinicians can elevate exercise into their therapeutic repertoire. An activation plan with tele-coaching, tracking tools, and behavioral linkage offers a pragmatic pathway to embed exercise as "medicine" for mood and anxiety disorders. While exercise does not replace medications or psychotherapy in more severe cases, its favorable risk–benefit profile, dual physical and mental health dividends, and client-empowering nature make it an indispensable adjunct in contemporary behavioral healthcare.

Mindfulness-Based Cognitive Therapy (MBCT) & Mindfulness Programs: Clinical Role, Protocols, Indications and Integration

Mindfulness-based approaches have risen in prominence over the last decade as clinically meaningful adjuncts for mood and anxiety disorders. Among these, Mindfulness-Based Cognitive Therapy (MBCT) stands out for its specific design to prevent relapse in recurrent major depression, manage residual symptoms, and address cognitive processes such as rumination and worry. For behavioral-health providers, understanding MBCT's clinical role, its typical 8-week protocol (including telehealth/group adaptations), its primary indications (residual symptoms, recurrent major depressive disorder [MDD], comorbid anxiety/rumination), and strategies for integration with behavioral activation and values-based work is essential. Moreover, outcome measurement, using tools such as the PHQ-9 and GAD-7, is key to tracking progress.

Clinical Role of MBCT & Mindfulness Programs

Originally developed by Segal, Williams and Teasdale to address relapse in recurrent MDD, MBCT combines mindfulness meditation practices with cognitive therapy techniques (Segal, Williams & Teasdale, 2002). Contemporary research confirms that MBCT effectively

reduces depressive symptom severity and, importantly, reduces relapse/recurrence risk in populations with prior depression episodes. A recent individual-participant data meta-analysis revealed that MBCT was associated with a hazard ratio of 0.69 (95% CI 0.58-0.82) for relapse compared with non-MBCT treatments across 1,258 participants (Kuyken et al, 2016. Further, a 2023 systematic review and network meta-analysis of psychological interventions in relapse prevention found that MBCT demonstrated significant benefit over placebo at 3, 6 and 9 months follow-up; benefits at later timepoints were less well sustained, but the effect was robust in the earlier period (Zhou et al, 2023). A newer review noted durability of effect up to six months in treatment-resistant depressed clients (Mira et al, 2023).

Beyond depression, MBCT and other mindfulness-based programs show efficacy in reducing anxiety symptoms, improving emotional regulation, and enhancing cognitive flexibility and decentering (Burgdorf et al., 2024; see review by Xu et al., 2024). For older adults and those with high rumination or worry, mindfulness interventions show promise in reducing risk of relapse, improving resilience and reducing cognitive-emotional reactivity (Jha et al., 2023). Thus, MBCT is well positioned as a maintenance/preventive intervention (preventing relapse), as well as an adjunctive intervention for residual symptoms (persistent low mood, rumination) and comorbid anxiety.

The standard MBCT protocol spans 8 weeks, typically in a group format of 8 sessions (one per week, 2–2.5 hours each) plus a full-day retreat around week 6. Daily home practice of 30–45 minutes is set, with guided mindfulness meditations, mindful movement (e.g., walking meditation, light yoga), and cognitive exercises relating to recognizing automatic thoughts, decentering, and mindful responding to mood cues. A meta-analysis of 13 RCTs (n = 1,159) found MBCT sessions lasting 1.5–2.5 h over 8 weeks were effective in reducing depression and suicidal ideation (Tseng, H.-W., Chou, F.-H., Chen, C.-H., & Chang, Y.-P. (2023).

Recognizing dissemination needs and telehealth realities, many programs have successfully adapted MBCT for online or hybrid delivery (e.g., 90-minute sessions via videoconference, digital home-practice portals, online retreat mini-day). Telehealth group formats are viable for behavioral-health contexts, provided the facilitator ensures process fidelity, group cohesion, and homework adherence.

For fidelity, core components to maintain are: (a) formal mindfulness practices (body scan, sitting meditation, walking meditation), (b) cognitive elements (recognition of early warning signs of relapse, automatic thinking, decentering), (c) group discussion and inquiry, (d) home-practice logs and adherence monitoring, and (e) relapse-prevention themes (e.g., planning for future mood shifts). In behavioral health settings, a

worksheet/handout summarizing weekly home-practice (e.g., number of minutes, type of practice, barriers, mood rating) is recommended.

Clients who have responded to treatment for MDD or GAD but continue to experience sub-threshold symptoms (e.g., PHQ-9 = 8-12, GAD-7 = 7-10) benefit from MBCT targeting rumination and worry loops. The decentering and mindfulness skills help disrupt cognitive reactivity and reduce risk of escalation.

For clients with a history of two or more prior major depressive episodes, MBCT is indicated for relapse prevention. Meta-analytic evidence shows relative risk reductions in relapse of 30-40% in such cases. According to subgroup analyses, the effect is stronger for those with three or more prior episodes.

Although originally designed for depression, MBCT and mindfulness programs are increasingly recommended for co-occurring anxiety disorders or mixed depression/anxiety presentations. Studies show reductions in anxiety symptom severity and improved coping with worry and rumination (Bockting et al., 2024). For instance, a systematic review of mindfulness interventions found improvements in anxiety, stress, and cognitive reactivity.

Emerging data indicate older adults with sub-syndromal depressive symptoms (and higher rumination) may particularly benefit from mindfulness programs, offering gentler, self-regulated, group-supported relapse-prevention strategies.

Providers can integrate MBCT with BA by linking mindfulness practice to valued action. For example, after a sitting meditation on noticing mood, the clinician can help the client identify a valued action (e.g., social contact, volunteering) and schedule it mindfully (aware of thoughts/feelings, applying decentering when cognitive obstacles emerge). This aligns mindfulness with activation, helping to translate insight into movement. Values clarification sessions can precede home-practice planning, allowing clients to anchor mindfulness and subsequent action in life-goals, thus enhancing meaning and adherence.

In resource-limited settings, providers may refer to an MBCT group (in-house or via telehealth) and maintain individual sessions for bridging each week's lesson with the client's context. Homework logs (minutes, type, obstacles, mood rating pre/post) can be incorporated into EHR or shared via digital portal, allowing the individual provider to monitor adherence and patterns (e.g., number of skipped days correlates with mood dips).

Outcome measurement

For standardization and clinical governance, use measures such as the PHQ-9 (depressive symptoms), GAD-7 (anxiety symptoms), and a functional measure such as WHO-5 or Role Functioning Scale at baseline, week 4, post-intervention (week 8 or 9), and

at follow-up (3, 6 months). Because MBCT aims at relapse/glow-maintenance, the provider should also monitor time to next episode, number of days depressed, and rumination/worry severity (e.g., using the Ruminative Responses Scale). A recent IPD meta-analysis found that MBCT's benefit did not significantly vary by age or number of previous episodes, implying broad applicability in real-world settings.

The 2023 network meta-analysis (Zhou et al., 2023) of 2,871 clients across 25 RCTs found MBCT significantly superior to placebo at 3, 6, and 9 months follow-up for relapse prevention (OR range ~3.7 to 12.9 vs. placebo) though long-term (≥15 months) evidence was less robust. PMC Similarly, a 2024 review (Li et al., 2024) concluded MBCT reduces both depressive and anxiety symptoms, enhances cognitive regulation, and supports subjective wellbeing across populations (turn0search14). Given this evidence, MBCT is best conceptualized as adjunctive to ongoing care (medication or psychotherapy) rather than as a stand-alone option for acute major depression in most cases.

Although older meta-analyses (e.g., Kuyken et al., 2016) showed MBCT comparable to maintenance antidepressant medication for relapse prevention, real-world translation requires attention to home-practice adherence, group format fidelity, and participant readiness. For example, participants with higher baseline rumination derive greater benefit, indicating that clinical selection (rumination-dominant, recurrent depression) enhances efficiency (turn0search1). Importantly, in older adult or medically-complex populations, MBCT's low-risk profile and group format may offer pragmatic maintenance strategies, underscoring its value in stepped-care maintenance/prevention rather than acute intervention.

While MBCT is robustly supported for relapse prevention and residual symptoms, it is not typically first-line monotherapy for acute moderate-to-severe MDD without parallel pharmacotherapy or psychotherapy, unless clinically indicated and client consents to this orientation. Further, many trials involve well-motivated participants with prior mindfulness exposure; in less motivated clients homework non-adherence may weaken effect. A key predictor of success is initial commitment to home practice (≥3–4 days/week). Also, the long-term durability beyond 12–15 months remains less well-studied (turn0search3). Group format logistics (e.g., scheduling, cost) may constrain scalability in some settings; many providers mitigate this by telehealth hybrid models. Finally, clients with active mania, psychosis, or severe cognitive impairment may not be appropriate for standard MBCT without adaptation.

For providers aiming to integrate evidence-based, sustainable adjunctive therapies for depression and anxiety, MBCT and mindfulness programs hold distinct advantages: they address rumination, bolster relapse prevention, foster self-regulation, and blend well with

values-driven activation and behavioral interventions. The protocol (8 weeks, group/telehealth, daily home practice) is replicable, and indications align with residual symptoms, recurrent MDD, and comorbid anxiety/worry predominant profiles. Measures such as the PHQ-9, GAD-7 and functioning scales provide monitoring frameworks. Although MBCT does not replace pharmacotherapy or psychotherapy in all cases, it occupies an important tier in stepped-care maintenance/preventive pathways, especially for clients motivated to engage in mindfulness practices and commit to home practice. With careful referral, monitoring and integration, MBCT can enhance long-term outcomes, reduce relapse risk and offer clients a powerful tool for self-management and resilience.

Yoga, Tai Chi & Qigong (Mind-Body Movement) for Depression and Anxiety

Mind-body movement therapies such as yoga, tai chi, and qigong represent an expanding frontier in integrative behavioral healthcare. Long rooted in contemplative traditions, these practices have evolved into evidence-based interventions demonstrating measurable benefits for mood and anxiety disorders. For behavioral health providers, they offer accessible, low-risk, body-centered strategies that complement psychotherapeutic and pharmacologic care. Recent systematic reviews and meta-analyses underscore their capacity to reduce depressive and anxiety symptoms, enhance quality of life, and foster long-term emotional regulation.

Yoga has accumulated a strong empirical foundation as an adjunctive treatment for depression and anxiety. A 2024 systematic review and meta-analysis published in Depression and Anxiety examined randomized controlled trials of yoga interventions for depressive disorders and found statistically significant improvements in depressive symptom severity when compared with passive controls (Vancampfort et al., 2024). Participants practicing yoga demonstrated higher remission rates relative to both active and passive comparators, with effects persisting after sensitivity analyses. The authors emphasized that integrating breath work and meditative focus into physical postures amplifies these benefits, suggesting that the mind-body synchronization inherent in yoga may uniquely target ruminative and stress-related cognitive patterns. A 2023 meta-analysis of yoga-based interventions for anxiety disorders reported that yoga outperformed control conditions in reducing anxiety severity and improving mood, even after adjusting for trial quality (Martínez-Calderón et al., 2023). These findings confirm that yoga interventions, whether delivered in studio, group medical, or home-based telehealth formats, can be reliably recommended as low-intensity adjuncts for clients experiencing anxiety or stress-related symptomatology. Notably, yoga interventions have demonstrated particular value in populations with chronic medical illness, postpartum depression, and

trauma-related dysregulation, where movement-based mindfulness may enhance interoceptive awareness and reduce avoidance behaviors.

Parallel progress has emerged for tai chi and qigong, two traditional Chinese movement therapies emphasizing slow, rhythmic motion coordinated with breathing and focused attention. A 2024 network meta-analysis of mind-body exercises in older adults found that tai chi and qigong significantly improved both depressive and anxiety symptoms, with standardized mean differences of –0.52 and –0.84 respectively (Wang et al., 2024). Similarly, a 2024 meta-regression of tai chi and qigong in cancer survivors documented small-to-moderate reductions in depression and anxiety and improvements in fatigue and sleep quality (Li et al., 2024). Another systematic review of stress-reduction interventions confirmed that tai chi programs yielded reductions in perceived stress comparable to mindfulness-based cognitive therapy, underscoring shared mechanisms of autonomic regulation (Liu et al., 2023).

Collectively, these studies converge on a clear conclusion: regular participation in structured mind-body movement such as yoga, tai chi, or qigong, produces clinically meaningful reductions in depressive and anxiety symptoms. The magnitude of benefit is generally moderate, comparable to outcomes observed with other lifestyle-based interventions such as aerobic exercise or mindfulness meditation, and superior to usual-care or wait-list controls. Moreover, these modalities exhibit high acceptability and low attrition rates, an important consideration for clients who may be ambivalent about medication or long-term psychotherapy.

The therapeutic mechanisms underlying these practices reflect an intersection of physiological and psychological processes. On the biological level, mind-body movement modulates inflammatory signaling and hypothalamic–pituitary–adrenal (HPA) axis reactivity, reducing circulating cortisol and pro-inflammatory cytokines associated with depressive pathophysiology (Wang et al., 2024). Neuroimaging research indicates increased activity and gray-matter density in the prefrontal cortex and hippocampus among long-term practitioners, regions integral to emotion regulation and cognitive control. Psychologically, these practices cultivate interoceptive awareness, self-compassion, and acceptance, thereby attenuating rumination and avoidance behaviors that perpetuate both depression and anxiety. The rhythmic, breath-centered movement of tai chi and qigong also promotes parasympathetic activation and improved vagal tone, contributing to a calmer baseline arousal state and enhanced resilience under stress.

In clinical practice, the recommendation of yoga typically involves two to three sessions per week of 45 to 60 minutes each, emphasizing integration of breath, gentle postures, and short meditation segments. The majority of effective trials used programs lasting eight to

twelve weeks, with total exposure exceeding 24 hours of instruction or practice (Vancampfort et al., 2024). Providers should encourage clients to engage in both formal classes and informal daily practice, brief morning stretches, mindful breathing, or short guided meditations, to reinforce skills. For clients preferring telehealth, online video programs supplemented by weekly clinician check-ins can sustain adherence.

Tai chi and qigong programs are generally prescribed two to five times per week, 20–45 minutes per session. Evidence suggests that higher frequency correlates with larger effects on depressive and anxiety outcomes, particularly in older adults (Zhang et al., 2025). The practice involves slow, flowing sequences combined with diaphragmatic breathing and sustained attentional focus. Many clients describe a meditative calm arising within ten to fifteen minutes, paralleling relaxation-response mechanisms known to lower autonomic arousal. For clients with limited mobility or chronic pain, seated or modified versions remain effective, allowing accessibility across age and fitness levels.

When recommending mind-body movement as a behavioral intervention, clinicians should articulate clear goals, such as mood stabilization, anxiety regulation, or sleep improvement, and link these goals to measurable outcomes (e.g., reductions in PHQ-9 or GAD-7 scores over 8–12 weeks). Integrating these practices into behavioral-activation or values-based frameworks can further enhance engagement. For instance, clients might identify “nurturing the body with awareness” as a valued action, then track participation as part of weekly activation assignments. Telehealth adaptations may include secure video platforms for guided practice, adherence trackers, and asynchronous message-based coaching to address barriers such as motivation or scheduling.

Although yoga, tai chi, and qigong are generally safe, thoughtful screening and modification are essential. Behavioral-health providers should assess musculoskeletal integrity, balance, and cardiovascular status prior to referral. Clients with orthopedic conditions, chronic pain, or balance difficulties may begin with gentle or chair-based versions to prevent falls and strain. Individuals with uncontrolled hypertension, severe heart disease, or vertigo should obtain medical clearance before initiating moderate movement programs.

Psychologically, these practices are well-tolerated, but certain individuals, particularly those with trauma histories, may initially experience distress when focusing on bodily sensations. Clinicians can mitigate this by introducing grounding exercises, shorter practice durations, and trauma-sensitive instruction emphasizing choice and safety. For clients with active psychosis, mania, or severe cognitive impairment, unsupervised practice is not recommended; modifications or concurrent stabilization should precede mind-body work.

Adverse events in literature are rare and typically mild (e.g., muscle soreness or transient dizziness). Nonetheless, documentation of informed consent and risk education is recommended. Clinicians should advise clients to report pain, lightheadedness, or mood worsening during practice. Coordination with certified instructors familiar with mental-health populations enhances safety and fidelity. Behavioral-health documentation might read: “Client engaged in adjunctive yoga practice, 45 minutes twice weekly for eight weeks, integrating breath work and meditation; baseline PHQ-9 = 14, GAD-7 = 11; re-evaluation scheduled at week 8.”

Clinical Integration

Mind-body movement fits seamlessly within stepped-care models as a Tier 1 or Tier 2 adjunct, providing early-stage intervention or relapse prevention for clients with mild-to-moderate symptoms or residual distress. In community settings, these practices can be implemented through small groups facilitated by clinicians or external instructors. Integration with psychotherapy enhances efficacy: cognitive-behavioral therapists may pair yoga breathing with exposure-based work to reduce physiological reactivity, while acceptance-based therapists can frame mindful movement as a tool for values-consistent living.

Outcome monitoring should combine symptom measures (PHQ-9, GAD-7) with quality-of-life indicators (WHO-5, SF-12). Behavioral-health teams can also track adherence metrics, number of sessions completed, minutes practiced per week, or self-reported enjoyment, to gauge feasibility. Evidence suggests that consistent practice over 8–12 weeks yields significant symptom reduction, with continued maintenance (one to two sessions weekly) sustaining gains and preventing relapse (Zhang et al., 2025). Providers should reinforce continuity by linking clients to community resources or online follow-up programs after the structured intervention ends.

Comparative and Population-Specific Considerations

For younger or middle-aged adults with high occupational stress, yoga may be particularly acceptable due to its familiarity and availability. In contrast, tai chi and qigong show stronger evidence in older adults and individuals with chronic illness, owing to gentler physical demands and social support embedded in group classes. Cancer-survivor studies highlight additional benefits for fatigue, sleep, and perceived well-being (Li et al., 2024). In multicultural settings, acknowledging cultural origins and respecting traditions enhances client engagement and avoids cultural appropriation. The universality of mindful movement allows adaptation across diverse populations, making it an inclusive therapeutic modality.

Yoga, tai chi, and qigong represent empirically supported, practical tools to complement traditional depression and anxiety treatments. Recent meta-analytic evidence confirms that yoga reduces depressive symptoms and promotes remission relative to passive controls (Vancampfort et al., 2024), that yoga-based interventions improve anxiety outcomes (Martínez-Calderón et al., 2023), and that tai chi and qigong yield meaningful improvements in both depression and anxiety across older-adult and chronic-illness populations (Wang et al., 2024; Li et al., 2024; Zhang et al., 2025). A reasonable clinical prescription involves two to three weekly yoga sessions of 45–60 minutes incorporating breath and meditation, or tai chi/qigong practice two to five times per week for 20–45 minutes focusing on slow, balanced flow. With appropriate screening for musculoskeletal or cardiovascular limitations and adaptation for psychological safety, these interventions present minimal risk and substantial potential benefit. By integrating mind-body movement into routine care, through group programs, telehealth coaching, and measurable outcome tracking, clinicians can offer clients holistic tools that engage both body and mind. In doing so, they help bridge the divide between physical activity and emotional healing, promoting resilience, balance, and sustained recovery.

Acupuncture for Depression & Anxiety

In recent years, acupuncture has increasingly entered the domain of mental-health adjunctive treatments. The evidence for acupuncture in depressive disorders shows promising, though still maturing, findings. A 2024 systematic review (registered under CRD42023443711) evaluated acupuncture versus conventional pharmacotherapy and reported that acupuncture "exhibits significant efficacy as a standalone treatment after four weeks of intervention, with fewer side-effects and adverse reactions" compared to standard treatments, though the authors noted the need for further high-quality trials (Zhang et al., 2024). Specifically, the meta-analysis indicated meaningful effect sizes for acupuncture in reducing HAMD (Hamilton Depression Rating Scale) scores, and lower adverse event rates compared to medication arms.

An earlier, widely cited meta-analysis (2019) of 29 trials ($n \approx 2{,}268$ participants) found that acupuncture produced clinically significant reductions in depressive severity compared with usual care (Hedges $g = 0.41$), compared with sham acupuncture ($g = 0.55$), and when used adjunctively with antidepressants ($g = 0.84$). While this review primarily included studies up to that time, the effect size of $g \approx 0.4–0.5$ suggests a moderate benefit, and the larger g when used adjunctively implies stronger effects when combined with standard treatments. Importantly, the meta-regression found a significant correlation between greater number of acupuncture treatments and larger effect size ($p = 0.015$) (Armour, Smith, Wang, Naidoo, Yang, MacPherson, & Hay, 2019).

A more recent review emphasizes that acupuncture “has garnered substantial clinical and experimental validation for its efficacy in addressing diverse forms of depression” including post-stroke, postpartum and adolescent depression (Li et al., 2024). BioMed Central ratings of adverse events show no substantial increased risk of serious harms compared to comparators; thus, acupuncture appears to possess a favorable risk profile in these populations.

Beyond primary mood disorders, acupuncture shows meaningful benefit in comorbid conditions with high mood/anxiety burden. For example, a 2024 meta-analysis of clients with IBS-D (irritable bowel syndrome, diarrhea predominant) and comorbid anxiety and depression found that acupuncture improved HAMD, HAMA (Hamilton Anxiety Scale), SDS (Self-rating Depression Scale), SAS (Self-rating Anxiety Scale) and other outcome indices in comparison to oral medications; for example, HAMA: MD = 2.32 (95% CI [1.70, 2.93], $p < .00001$) and SDS: MD = 9.84 (95% CI [8.52, 11.16]). (Wang et al., 2024). Additionally, another meta-analysis of acupuncture for anxiety/depression in clients with functional dyspepsia (FD) reported a positive effect, albeit with limitations in number and quality of included RCTs (Liu, Gao, Ou, Tang, Zhao, Hua, & Xiong, 2024).

More generally, a 2024 review of acupuncture-related therapies for anxiety and depression in clients with ovarian hypofunction reported effect sizes of SMD = –0.82 for depressive symptoms and –0.90 for anxiety symptoms (95% CI –1.25 to –0.40; –1.28 to –0.53 respectively) across 12 RCTs (n = 780) (Huang, Zhang, Shi, Zhang, Wang, She, Liang, Li, & Zaslawski, 2024).

A recent overview of the state of evidence in acupuncture (covering 2017–2022) found that while the volume and methodological quality of meta-analyses have increased, important gaps remain in standardization of protocols, blinding, and long-term follow-up data (Yuan et al., 2022). Acupuncture yields moderate effect sizes for depressive and anxiety symptoms, particularly when used adjunctively; it shows acceptable safety and tolerability; and it holds additional promise in complex or comorbid populations (e.g., IBS, FD) where mood/anxiety are intertwined with somatic/chronic illness. However, the evidence has yet to reach the level of large, high-quality, blinded trials with long-term follow-up that many pharmacologic treatments have—so clinicians should view acupuncture as an adjunctive option rather than a standalone first-line replacement in most cases.

Providers committed to offering integrative, client-centered care, acupuncture presents a viable adjunctive option in the treatment of depression and anxiety. The evidence base now includes moderate effect sizes for depressive symptom reduction (Hedges $g \approx 0.4–0.5$) and improvements in anxiety symptoms and quality of life in comorbid populations such as IBS

and ovarian hypofunction (Armour, Smith, Wang, Naidoo, Yang, MacPherson., Lee, & Hay, (2019). The favorable safety and acceptability profile further supports its role. Clinically, an initial protocol of twice-weekly sessions for 4–6 weeks followed by reassessment is pragmatic. Coordination with medication and psychotherapy is essential, and outcomes should be measured using PHQ-9, GAD-7, and functional/QoL scales with predefined decision points for continuation or modification. Given the still-developing quality of evidence (especially long-term follow-up), acupuncture should be positioned as an adjunctive rather than standalone treatment in most cases. With appropriate client selection, monitoring, and documentation, acupuncture can enrich the behavioral-health provider's toolkit, particularly for clients who prefer integrative approaches or present with comorbid somatic conditions.

Light-Based Therapies

Light-based interventions have re-emerged as scientifically credible, non-pharmacologic options for managing mood disorders, particularly depression. Among these, Bright Light Therapy (BLT) and Photobiomodulation (PBM) offer distinct but complementary mechanisms for improving affective and circadian regulation. For behavioral-health providers, understanding current evidence, therapeutic parameters, and safety precautions is essential before integrating light-based approaches into care plans.

Bright light therapy involves controlled exposure to full-spectrum or high-intensity (typically 10,000 lux) white light, simulating natural daylight. Historically used for Seasonal Affective Disorder (SAD), its utility has expanded to non-seasonal depression and depressive symptoms in medical and older-adult populations. A 2024 systematic review and meta-analysis of randomized controlled trials in adults aged 60 years and older found that bright light therapy significantly reduced depressive symptom scores compared with control conditions (SMD = –0.47, 95 % CI [–0.69, –0.25]) (Zhu et al., 2024, PMC 11306693). Effect sizes were greatest in trials employing higher intensities (≥ 5,000 lux) and morning exposure protocols of 30–60 minutes daily over 2–6 weeks. The authors concluded that BLT "is an effective and safe adjunctive therapy for depressive symptoms in older adults," particularly when combined with sleep-schedule stabilization and activity structuring.

Similarly, a 2023 meta-analysis in mixed-age samples (n = 2,154) reported moderate efficacy of BLT for both seasonal and non-seasonal depression, with response rates nearly doubling compared to placebo light (54 % vs 29 %), and minimal adverse effects (fatigue, headache, mild agitation) (Lee et al., 2023). Importantly, trials combining BLT with antidepressant pharmacotherapy yielded the strongest outcomes, suggesting synergy with serotonergic modulation.

Mechanistically, BLT is thought to exert antidepressant effects by entraining circadian rhythms via melanopsin-containing retinal ganglion cells that project to the suprachiasmatic nucleus (SCN). Morning light exposure suppresses melatonin earlier, advancing circadian phase, improving sleep timing, and enhancing daytime alertness. Functional imaging studies reveal that BLT increases prefrontal cortical activation and normalizes amygdala-prefrontal connectivity, supporting improved emotion regulation (Zhu et al., 2024). Clinically, behavioral-health providers can recommend morning sessions of 10,000 lux white light for 30 minutes at ~50 cm distance (eyes open but not staring directly). The therapy can begin at 15–20 minutes daily and titrate up as tolerated. For clients with insomnia or delayed sleep phase, timing should shift earlier (6:30–8:00 a.m.) to advance circadian rhythm. Response is typically seen within 2–4 weeks. Maintenance sessions may be reduced to 3–4 days weekly once remission is achieved.

Photobiomodulation (PBM)

Photobiomodulation (PBM), also known as transcranial near-infrared light therapy, represents a rapidly advancing frontier in non-invasive neuromodulation for mood and anxiety disorders. By applying low-level red or near-infrared light (typically 600–1,100 nanometers) to the scalp, PBM directly influences neuronal bioenergetics. The light photons are absorbed by mitochondrial chromophores, particularly cytochrome c oxidase (CCO), which serve as photo-acceptors and catalysts for adenosine triphosphate (ATP) synthesis. Increased ATP availability enhances neuronal metabolism, promotes cellular repair, and supports synaptic plasticity, all of which are critical for optimal brain function and emotional regulation.

Unlike Bright Light Therapy (BLT), which primarily acts through retinal stimulation and circadian entrainment, PBM penetrates the skull and targets cortical tissue directly. Functional imaging studies show that transcranial PBM enhances regional cerebral blood flow and oxygenation, particularly in the dorsolateral prefrontal cortex (DLPFC**)**, a region implicated in mood regulation, cognitive control, and executive functioning. This neurophysiological effect aligns with the observed clinical improvements in depressive symptoms and cognitive performance across preliminary trials.

Emerging research further suggests that PBM may reduce oxidative stress and neuroinflammation, modulate glutamate and GABA neurotransmission, and normalize default mode network connectivity, mechanisms believed to underlie mood stabilization. Treatment protocols generally involve 20–30 minute sessions two to three times per week over four to six weeks, using FDA-cleared near-infrared LED devices. Because PBM is painless, low-risk, and compatible with concurrent psychotherapy or pharmacotherapy, it

is increasingly viewed as a promising adjunctive tool within integrative behavioral healthcare, supporting both neurobiological recovery and cognitive vitality.

A 2024 systematic review and meta-analysis encompassing 14 clinical trials (n = 684) concluded that transcranial PBM significantly improved depressive symptoms compared with sham conditions, with pooled SMD = –0.62 (95 % CI [–0.90, –0.34]) and a number-needed-to-treat of ≈ 4 (Fang et al., 2024, PMC 10870324). Most studies involved adults with major depressive disorder, subthreshold depression, or comorbid anxiety. Effective parameters included wavelengths between 810–1,064 nm, power density ≈ 100 mW/cm^2, treatment duration 20–30 minutes per session, and total course 8–12 sessions over 4–6 weeks. Symptom improvement was accompanied by increased regional cerebral blood flow in the dorsolateral prefrontal cortex (DLPFC) and normalized connectivity in the default-mode network on fMRI. A complementary 2023 narrative synthesis highlighted that PBM improves cognitive processing speed, emotional regulation, and sleep quality, with minimal adverse events (mild scalp warmth, transient headache) (Salehpour et al., 2023, PMC 10707186). The review emphasized parameter sensitivity, dose, wavelength, and site placement determine therapeutic yield. The DLPFC is the most common target region due to its involvement in executive function and mood regulation.

Comparative studies suggest PBM may achieve effect sizes comparable to repetitive transcranial magnetic stimulation (rTMS) but with lower cost, easier delivery, and minimal side effects. However, high-quality, large-scale RCTs are still limited, and blinding remains challenging due to the perceptible warmth of active devices.

In practice, PBM can be delivered via FDA-cleared near-infrared LED devices positioned over the forehead or scalp. Providers coordinating PBM should verify that the device's specifications (wavelength, irradiance, treatment time) align with published protocols. Treatment frequency commonly begins at two to three sessions per week for the first month, followed by weekly maintenance as needed. Coordination with psychotherapy or pharmacotherapy is essential to optimize synergy and manage expectations.

Safety, Contraindications, and Monitoring

Both BLT and PBM have favorable safety profiles but require careful screening and client education. For bright light therapy, the primary risks involve circadian misalignment and manic activation. Providers should screen for bipolar disorder, as morning light exposure can precipitate hypomania or mania. To minimize risk, start with shorter sessions (15–20 min) at 5,000 lux, increase gradually, and monitor for mood elevation, decreased sleep need, or increased goal-directed behavior. Clinicians should also monitor for sleep phase shifts, evening light exposure may delay circadian rhythm and worsen insomnia. Morning

use remains preferred. Clients with ocular conditions (e.g., macular degeneration, retinal disease) should consult ophthalmology prior to initiation. For photobiomodulation, eye safety and energy-dose calibration are key. Clients should wear protective goggles during sessions to prevent accidental retinal exposure. Contraindications include active malignancy in the head/neck, pregnancy (forehead exposure), and epilepsy (due to potential photic sensitivity). Side effects are generally mild: transient headache, scalp warmth, or lightheadedness. No serious adverse events have been reported in modern PBM trials (Fang et al., 2024; Salehpour et al., 2023). Providers should document screening results, informed consent, and safety instructions in the clinical record.

Light-based therapies align naturally with behavioral activation and circadian-stabilization strategies used in cognitive-behavioral and acceptance-based frameworks. Behavioral-health providers can embed BLT or PBM within comprehensive plans emphasizing sleep hygiene, activity scheduling, and mindfulness. For example, BLT sessions can occur immediately after waking, followed by morning exercise or journaling to consolidate circadian entrainment and behavioral momentum.

In telehealth contexts, clinicians can supervise BLT remotely by verifying device specifications and timing adherence via self-report or wearable data. PBM typically requires in-office administration or collaboration with medical colleagues, but emerging at-home protocols may expand accessibility. Clients should be informed that light therapies are adjunctive: while effective, they do not replace pharmacotherapy or structured psychotherapy in moderate-to-severe depression. They are especially suitable for residual symptoms, seasonal patterns, fatigue, or sleep-wake dysregulation.

Bright light therapy and photobiomodulation represent practical, well-tolerated adjuncts for depression and anxiety management. Evidence demonstrates that BLT significantly reduces depressive symptoms, particularly in older adults and in morning high-intensity applications (Zhu et al., 2024). PBM's emerging data suggest comparable benefits, with measurable neural and metabolic changes using near-infrared stimulation (Fang et al., 2024; Salehpour et al., 2023). When implemented with careful screening for bipolar activation and attention to ocular and circadian safety, these therapies can meaningfully enhance mood, energy, and quality of life. Behavioral-health providers adopting light-based interventions can thereby extend evidence-informed, low-risk options that integrate seamlessly with psychotherapy, pharmacotherapy, and lifestyle-based care.

Omega-3 Fatty Acids (EPA/DHA)

Long-chain omega-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerged in recent years as promising adjunctive

interventions for mood and anxiety disorders. For clinicians, understanding the evolving evidence base (2023–2025), how to translate that into practical discussions with clients, and how to integrate omega-3 supplementation into comprehensive care plans is essential.

Meta-analytic and narrative reviews of omega-3 fatty acids in mood and anxiety disorders demonstrate modest but clinically meaningful effects, particularly when EPA-rich formulations are used. A 2024 dose-response meta-analysis of 23 trials (n ≈ 2,189) found that supplementation with omega-3s resulted in a moderate decrease in anxiety symptoms (SMD = –0.70, 95% CI –1.17 to –0.22) with the greatest improvement at ~2 g/day (SMD = –0.93) and little improvement at lower doses (Bafkar et al., 2024). For depressive symptoms, recent meta-analyses and reviews underscore that formulations with a higher proportion of EPA (≥ 60%) and total EPA dose >1 g/day appear superior (Płatek et al., 2024; Jiang et al., 2024). For example, a comprehensive overview concluded that EPA-dominant supplements show stronger antidepressant effects, particularly when used adjunctively (Płatek et al., 2024). A 2024 Mendelian-randomization study also supported a causal role of omega-3 fatty acids, especially EPA, in the aetiology of depression (Carnegie et al., 2024).

Although older meta-analyses (2014–2021) reported small effect sizes and significant heterogeneity (SMDs ≈ –0.28) (e.g., Sublette et al., 2017), more recent work emphasizes key moderators: EPA dose, EPA:DHA ratio, trial design, placebo composition, baseline inflammation, and comorbid medical conditions (Płatek et al., 2024). For example, one review noted that an EPA:DHA ratio of ≥ 2:1, with EPA doses of 1–2 g/day, minimum 8 weeks' duration, were associated with the best outcomes (Płatek et al., 2024).

In augmenting major depressive disorder (MDD) treatment, pilot randomized controlled trials demonstrate enhanced response when EPA-rich supplements are added to antidepressants, though these remain smaller scale and require replication (Jiang et al., 2024). A recent narrative review highlights that individuals with elevated inflammatory biomarkers (e.g., C-reactive protein, IL-6) may derive greater benefit from ω-3s, pointing to a potential personalized medicine application (Płatek et al., 2024).

The current consensus suggests that omega-3 fatty acids, particularly EPA-dominant formulas, may offer adjunctive benefit for depressive and anxiety symptoms under certain conditions. Evidence quality remains moderate, and effects are not uniform across populations; therefore, these interventions should be framed as adjunctive rather than stand-alone in most cases.

From a mechanistic standpoint, omega-3 fatty acids exert effects through multiple convergent pathways: modulation of neuroinflammation (reduction of IL-6, TNF-α), improvement of membrane fluidity (especially neuronal membranes), enhanced neurotransmitter function (serotonin, dopamine), and promotion of synaptic plasticity and neurogenesis (particularly in the hippocampus) (Malau & Colleagues, 2024; Zhou & Colleagues, 2022). The fact that individuals with elevated inflammatory markers appear to benefit more suggests that omega-3s may serve as "inflammation-targeted treatments" for a depression/anxiety subtype ("inflamed depression") (Malau & Colleagues, 2024).

In clinical application, moderators that influence response include: baseline inflammation status, EPA dose and ratio, trial/comparator design (placebo oils may not be inert), client dietary intake of omega-6 fatty acids (high omega-6:omega-3 ratio may reduce benefit), and timing/duration of supplementation (≥8 weeks yields better results) (Li et al., 2025; Malau & Colleagues, 2024). One systematic review noted that omega-3 supplementation monotherapy produced smaller effects compared to augmentation trials, suggesting omega-3s are best viewed as adjuncts (Malau & Colleagues, 2024). Medium toward large effect sizes are typically found when EPA dose is high, ratio proper, and other treatments stable. Providers should therefore discuss with clients that omega-3 supplementation is not a quick fix; benefit accrues over weeks, and best results come when combined with standard treatment and lifestyle interventions (diet, exercise, sleep, stress management).

Safety, Contraindications and Monitoring

Omega-3 fatty acids are generally well tolerated and possess a favorable safety profile, making them an appealing adjunct in behavioral-health settings. The most common side effects are mild gastrointestinal complaints such as "fishy burps," nausea, or occasional loose stools. Doses of combined docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) up to 4 g per day have been used safely in large cardiovascular trials, though mood-disorder studies typically employ lower dosages.

From a clinical standpoint, several safety considerations should guide behavioral-health providers when recommending omega-3 supplementation. First, bleeding risk should be evaluated because omega-3s exert mild anti-platelet effects. Clients taking anticoagulants (e.g., warfarin or direct oral anticoagulants) or antiplatelet medications (such as aspirin or clopidogrel), as well as those with bleeding disorders, should be monitored closely, and communication with the prescribing provider is essential. Second, in clients with bipolar spectrum disorders, omega-3s should be introduced only when mood is stable and under psychopharmacologic supervision. Although omega-3s rarely induce mania, caution is warranted when augmenting mood stabilizers.

A third concern involves supplement quality and label accuracy. Because dietary supplements are not as tightly regulated as prescription medications, clinicians should encourage clients to ask their physician to recommend products that are third-party tested for purity and potency, verify EPA/DHA content, and ensure absence of heavy-metal contamination. Selecting the appropriate form, such as triglyceride rather than ethyl-ester formulations, can also enhance absorption and tolerability. Interactions are uncommon but possible at high doses, as fish-oil supplementation may reduce platelet aggregation. Coordination with a client's medical team is needed when concurrent anticoagulant or antiplatelet therapy is in use.

Special populations require additional consideration. Omega-3s are generally regarded as safe during pregnancy and in older adults, yet formulation purity and comorbid medical conditions should influence selection. Evidence for psychiatric benefit in these groups remains limited, so individualized risk–benefit evaluation is recommended.

Finally, documentation should be thorough. Clinical notes should record baseline assessments such as bleeding risk and relevant hepatic or renal status, specify the chosen supplement and dosage (for example, "EPA-dominant formula, 2 g/day, EPA:DHA ≈ 2.5:1"), and reflect informed consent. Clients should be advised that evidence is moderate, effects may require eight or more weeks, and omega-3s are typically adjunctive rather than stand-alone treatments. Follow-up appointments with medical provide should occur after 8–12 weeks to assess response and tolerability. Any adverse events, such as mild gastrointestinal bloating, should be discussed and evaluated by client's medical provider.

Omega-3 fatty acids, particularly EPA-dominant formulations, offer a credible, evidence-informed option. The current body of literature shows modest but meaningful benefit (especially when EPA dose >1 g/day and EPA:DHA ratio ≥2:1), particularly when used alongside antidepressants or in populations with elevated inflammation. Clinically, a pragmatic approach involves encouraging client's to discuss the intervention with their medical provider. Safety is high, though provider screening for anticoagulation or bipolar risk remains necessary. As with all integrative interventions, omega-3s should be framed as adjunctive, embedded within comprehensive stepped-care that includes psychotherapy, pharmacotherapy, exercise, sleep and nutritional support. With this integrative mindset, omega-3 supplementation can enhance client engagement and potentially augment clinical outcomes in mood and anxiety disorders.

Botanicals & Nutraceuticals

Emerging interest in non-pharmacologic adjunctive therapies has stimulated research into botanicals and nutraceuticals for mood and anxiety disorders. Among these, three

compounds stand out for relatively robust trial data: saffron (Crocus sativus), S-Adenosyl-L-methionine (SAMe), and oral lavender essential oil (Silexan®). Though they are not replacements for first-line pharmacotherapy in most cases, evidence suggests potential efficacy, favorable tolerability, and plausible mechanisms worthy of consideration by providers.

Saffron (Crocus sativus)

The use of saffron extract in depressive and anxiety symptoms has been examined in systematic reviews and meta-analyses. One early meta-analysis of trials in mild-to-moderate depression found a large effect size (g = 0.891; 95 % CI: 0.369–1.412, p = 0.001) compared to placebo, and non-inferiority relative to antidepressants (g = –0.246; 95 % CI: –0.495 to –0.004, p = 0.053). (Moshiri et al., 2018) Another review noted that saffron supplementation significantly reduced self-reported depressive and anxiety scores (BDI, BAI) though effects on HDRS or HAM-A and CRP were less consistent (Shen et al., 2019). Moreover, an updated systematic review found saffron might contribute to alleviation of depression but cautioned that it cannot yet be considered a sole therapy (Hausenblas et al., 2021). In direct comparisons, a meta-analysis reported that saffron "could be a potential SSRI alternative" in reducing depressive and anxiety symptoms, albeit with a call for larger samples (Zeng et al., 2024).

In terms of dose and duration, most trials have used standardized extracts of ~30 mg/day (divided doses) over durations of 28–84 days. (Lopresti et al., 2020) [Turn0search10] While saffron appears generally well-tolerated, with only mild gastrointestinal upset reported, methodological issues remain such as small sample sizes, short follow-ups, regional homogeneity of samples, and potential placebo responses. Safety signals remain minimal to date (Ghaderi et al., 2019), but further high-quality trials are required. Mechanistically, saffron is thought to work via serotonergic modulation, antioxidant/anti-inflammatory pathways, and neuroprotective effects (Hosseinzadeh & Sadeghnia, 2022).

For clinicians, saffron may be discussed as an adjunctive option in mild to moderate depressive symptomatology, especially when clients prefer a "natural" add-on and standard treatments are tolerated but insufficient. It is important to emphasize that saffron is not yet established as a first-line monotherapy in major depressive disorder, and that product quality (standardized extracts), dosing consistency, and monitoring are essential.

S-Adenosyl-L-methionine (SAMe)

SAMe is a naturally occurring methyl donor involved in numerous biochemical pathways including neurotransmitter synthesis, methylation processes, and cell membrane phospholipid metabolism. As a nutraceutical, SAMe has been studied in depression both as monotherapy and adjunctively. A 2024 systematic review and meta-analysis found that

SAMe demonstrated efficacy and acceptability in treating depression (Wang et al., 2024). Earlier reviews reported that SAMe might be more efficacious than placebo and comparable to tricyclic antidepressants when administered parenterally, though evidence for oral administration was less consistent (Papakostas & Alpert, 2001). In the oral domain, trials report doses ranging from 200 mg to 3200 mg per day, usually for 2–12 weeks (Stubbs et al., 2020).

Typical dosing in modern studies ranges from 800 to 1,600 mg/day, titrated to tolerance, especially when used adjunctively. Safety signals are favorable, gastrointestinal effects (nausea, diarrhea) and occasional insomnia/activation have been noted; in bipolar spectrum disorders, activation risk should be assessed. SAMe's biological plausibility rests on methylation of catecholamines/serotonin, modulation of phospholipid turnover, and homocysteine region metabolism, thus co-consideration of B-vitamin (folate/B12) sufficiency is advisable for clinicians (Lai et al., 2023).

In practice, SAMe may be considered for clients with depression who have plateaued on standard antidepressants, as an adjunctive strategy under medical supervision. As with other nutraceuticals, emphasis on product quality (third-party certification), monitoring (liver/renal status if relevant), and informed consent about the moderate nature of evidence is important.

Lavender Essential Oil (Silexan®)

Silexan® is a standardized oral preparation of lavender essential oil (Lavandula angustifolia) designed for anxiety and related mood disorders. Meta-analyses demonstrate significant anxiolytic efficacy across subthreshold anxiety, generalized anxiety disorder (GAD), and mixed anxiety-depressive disorders. For example, one meta-analysis found that Silexan significantly improved investigator and patient-reported outcomes with favorable tolerability (Beyer et al., 2023). In another randomized trial, Silexan at 80 mg or 160 mg/day produced superior reductions in Hamilton Anxiety Rating Scale (HAMA) scores compared to placebo; in this study the mean HAMA score reductions were 14.1 ± 9.3 (160 mg) and 12.8 ± 8.7 (80 mg) versus 9.5 ± 9.0 for placebo ($p < 0.01$) (Woelk et al., 2022). Safety and tolerability are well-documented: sedation or dyspepsia may occur, but adverse event rates approximate placebo in trials (Gleiter et al., 2024). Dosing in clinical trials commonly uses 80–160 mg/day of Silexan capsules. A systematic review also noted that while aromatherapy may have short-term benefits, the oral Silexan formulation is preferable for sustained treatment (Hadjik et al., 2020).

For integration into practice, Silexan may be introduced by the client's medical provider as a single-agent for mild to moderate anxiety (6–8 weeks) or as augmentation for partial responders to SSRIs/SNRIs, with monthly outcomes measurement (e.g., GAD-7, PHQ-9,

WHO-5). Quality assurance (standardized extract, verified brand) should be stressed. Although the primary indication is anxiety, improvement in co-occurring depressive symptoms has also been documented (Hadjik et al., 2024).

Saffron (Crocus sativus), SAMe, and oral lavender essential oil (Silexan®) are botanicals/nutraceuticals supported by growing empirical evidence for adjunctive use in mood and anxiety disorders. Saffron shows moderate-to-large effect sizes in depressive symptoms and may be comparable to SSRIs in some pooled analyses, though high-quality long-term trials are lacking. SAMe demonstrates efficacy and acceptability in depression, particularly as adjunctive therapy, with plausible mechanistic underpinnings in methylation and neurotransmitter biology. Silexan offers clinically meaningful anxiolytic effects, with favorable safety and potential improvement of comorbid depressive symptoms. While none of these should currently replace evidence-based pharmacotherapy or psychotherapy as first-line treatments, providers may consider recommending clients to discuss with their medical provider in appropriate clients who prefer non-traditional agents, with clear informed consent, quality product selection, and systematic monitoring. Ongoing research will help refine dosing, identify moderators of response (e.g., inflammation, baseline biomarkers), and establish long-term safety and comparative effectiveness.

Non-invasive Vagus Nerve Stimulation

The Vagus Nerve (VN), a major component of the parasympathetic nervous system, has emerged as a key player in the pathophysiology of depression and anxiety through its widespread afferent and efferent connections linking the brain, cardiovascular system, immune system, and gut. The VN conveys visceral sensory information to the brainstem and subsequently to limbic, prefrontal, and autonomic regulation centers (Breit et al., 2018; Smith, 2015). Specifically, the VN influences brain regions implicated in mood and anxiety disorders (e.g., the locus coeruleus, dorsal raphe, and prefrontal cortex) via its afferent fibers (Grimonprez et al., 2015; Kraus et al., 2022).

In depression, multiple lines of evidence suggest **low vagal tone**, the measurable capacity of the vagus nerve to regulate autonomic and affective responses, may predispose individuals to dysregulated stress responses, heightened inflammation, and impaired neuroplasticity (Grimonprez et al., 2015; Tan et al., 2022). For example, low heart-rate variability (an index of vagal tone) correlates with severity of depressive and anxiety symptoms. The VN also modulates the hypothalamic-pituitary-adrenal (HPA) axis and inflammatory cascades: stimulation of vagal afferents can reduce pro-inflammatory cytokines, which are elevated in both depression and anxiety (Arbour et al., 2023; Krahl & Clark, 2015). Moreover, the VN is a critical conduit in the gut–brain axis: vagal afferent

fibers detect gut-microbiota-derived signals and influence brain circuits of mood regulation; disruptions in this pathway may contribute to both depressive and anxious symptomatology (Tan et al., 2022; Grimonprez et al., 2015).

Therapeutically, Vagus Nerve Stimulation (VNS) has been approved for treatment-resistant depression and has shown emerging promise for anxiety disorders. Meta-analyses suggest that VNS produces sustained antidepressant effects (Bajwa & Smith, 2020; see also Aronson et al., 2022) and may improve quality of life in severely depressed patients (Nahas et al., 2018). Anxiety outcomes have also improved in small-scale studies although data remain limited (Engineer et al., 2022). The combination of VN's modulation of monoaminergic systems, neuroplasticity enhancement, anti-inflammatory effects, and gut–brain communication underscores its integrative role in mood and anxiety disorders (Krahl et al., 2015; Tan et al., 2022).

Neuromodulation therapies leveraging the vagus nerve have expanded substantially in recent years across neurology and psychiatry. Originally approved for implantable VNS in treatment-resistant depression (TRD), the technology has since been adapted for adjunctive treatment of mood disorders and, more recently, as entirely non-invasive, transcutaneous auricular approaches (taVNS).

The implantable VNS device received approval from the U.S. Food and Drug Administration (FDA) in 2005 as an adjunctive treatment for chronic or recurrent treatment-resistant depression (TRD) in adults (Nahas et al., 2005, as cited in Rush et al., 2017). More recently, a comprehensive narrative review described "recent advances and future directions" in VNS across disease states including depression, emphasizing that VNS is emerging as a potent intervention in psychiatry (Ziemann et al., 2024). Long-term observational data continue to accumulate: a five-year registry study found that among patients with chronic, severe depression, adjunctive VNS plus treatment as usual achieved a cumulative 5-year response rate of 67.6% versus 40.9% in treatment-as-usual alone, and remission rates of 43.3% versus 25.7% (Aaronson et al., 2017). Complementary quality-of-life data show sustained improvements in daily functioning with VNS over 12-month horizons (Conway et al., 2018). Thus, while implantable VNS offers a well-established albeit resource-intensive option in TRD, its invasiveness and cost have limited widespread behavioral-health uptake.

The advent of transcutaneous auricular VNS (taVNS) has broadened access by delivering electrical stimulation via the auricular branch of the vagus nerve (ear/tragus) without surgery. Early work shows therapeutic effects on cognition, arousal, attention, emotional regulation, and behavioral control. For example, a 2023 meta-analysis concluded that taVNS was an effective and safe method for reducing depressive symptoms, demonstrating

response rates comparable to antidepressant treatments (Zhang et al., 2023). Prior reviews also highlight modulation of neurotransmitter systems, autonomic regulation, inflammation and functional connectivity as putative mechanisms for taVNS in mood/anxiety contexts (Wu et al., 2018). Clinical application of taVNS in mood/behavioural disorders is still in its early phases. For instance, a pilot randomized controlled trial found that taVNS significantly reduced BDI, HAM-D and HAM-A scores compared with sham in patients with major depressive disorder (Hein et al., 2013; as cited in Wu et al., 2018). A recent narrative review proposed that VNS remains a promising adjunct in TRD and that non-invasive taVNS may extend neuromodulation to less severe or earlier-stage mood/arousal disorders (Ziemann et al., 2024). While effect sizes, optimal stimulation parameters, and patient-selection criteria remain to be defined, the accumulating data suggest a growing role for taVNS in behavioral health.

Non-invasive VNS via auricular stimulation represents a promising neuromodulatory tool for behavioral health. Implantable VNS remains the best-documented intervention, especially for TRD, with regulatory approval and long-term outcome data. Non-invasive taVNS expands access and shows promising effects on cognition, arousal and emotional regulation, though the maturity of the evidence base lags. Behavioral-health providers exploring taVNS should focus on collaboration with medical providers, client education, rigorous documentation of device parameters and adherence, careful candidate selection and monitoring using standard outcome instruments. While taVNS should not yet replace established treatments, its favorable safety profile and emerging data support its use as an adjunct in selected clients. Ongoing trials will help refine stimulation protocols, clarify responder profiles, and establish long-term outcomes, particularly in mood and anxiety disorders.

Ethics, Informed Consent, Documentation, and Measurement

The integration of alternative and complementary therapies into the treatment of depression and anxiety presents both promising opportunities and complex ethical responsibilities. Clinicians increasingly encounter clients interested in non-pharmacologic adjuncts such as omega-3 fatty acids, S-adenosyl-L-methionine (SAMe), saffron, lavender oil, and transcutaneous vagus nerve stimulation (taVNS). While emerging evidence supports these modalities as beneficial adjuncts, they remain supplemental rather than curative. Their inclusion in practice requires a deliberate ethical framework grounded in informed consent, careful documentation, and structured measurement-based care.

Ethical Practice in Integrative Behavioral Health

Ethical integration begins with presenting alternative therapies as adjunctive options rather than replacements for empirically supported treatments such as cognitive-behavioral therapy (CBT) or pharmacotherapy. The American Psychological Association (APA) *Ethical Principles of Psychologists and Code of Conduct* emphasize beneficence and nonmaleficence, directing clinicians to "strive to benefit those with whom they work and take care to do no harm" (APA, 2017, Standard 3.04). The American Counseling Association (ACA) *Code of Ethics* (2014) similarly mandates that counselors practice within their "boundaries of competence" (C.2.a) and ensure interventions are grounded in scientific evidence. The National Association of Social Workers (NASW) *Code of Ethics* (2021) requires practitioners to obtain informed consent in understandable language (Standard 1.03) and to provide services within their scope of practice (Standard 1.04). Likewise, the American Association for Marriage and Family Therapy (AAMFT) (2015) specifies that marriage and family therapists "base services on established scientific and professional knowledge" and "avoid harming clients" (Principles I 1.1–1.2).

Applied to alternative approaches, these codes converge on several ethical imperatives: clinicians must not exaggerate claims of efficacy, must disclose uncertainties in the research base, and must ensure recommendations align with licensure and jurisdictional regulations. Ethical practice further demands transparency regarding any potential financial conflicts or affiliations with supplement or device manufacturers. Ultimately, practitioners' duty is to empower informed choice through evidence-based education rather than persuasion or product promotion.

Informed Consent

Informed consent serves as both a clinical process and a legal protection. It is particularly vital when using emerging or adjunctive treatments, where empirical evidence may still be developing. Ethical consent discussions should include the purpose of the intervention, potential benefits, foreseeable risks, reasonable alternatives, and the current limits of scientific knowledge (ACA, 2014; NASW, 2021).For example, when recommending omega-3 fatty acids, clinicians should note that meta-analyses support modest improvements in depressive and anxiety symptoms, especially for EPA-dominant formulations exceeding 1 g/day (Bafkar et al., 2024). Yet clients must be informed of possible gastrointestinal discomfort and bleeding risk if used concurrently with anticoagulants. With SAMe, clients should understand its evidence base for depressive disorders (Wang et al., 2024) and potential activation or insomnia, especially in those with bipolar vulnerability. Similarly, saffron and lavender oil (Silexan®) have demonstrated short-term efficacy for mild to moderate mood and anxiety symptoms (Li et al., 2024; Beyer et al., 2023), but quality and standardization of botanical supplements vary greatly. For taVNS,

informed consent should outline mild side effects, such as tingling or ear irritation, and emphasize that many devices remain under investigational status for mental health indications (Ziemann et al., 2024).

A robust informed-consent document should specify treatment goals, referral to medical provider, product or device details, expected duration (often 8–12 weeks before evaluating benefit), and ongoing monitoring methods. The discussion should reaffirm that these interventions are adjunctive, not substitutes for conventional care, and that clients may discontinue at any time without penalty. Written and verbal review ensures comprehension, promotes collaboration, and upholds the principle of respect for autonomy (APA, 2017, Standard 3.10).

Documentation

Ethical integration also requires meticulous documentation. Clinical records should describe the rationale for each intervention, the evidence supporting its use, and details such as brand, dosage, and frequency. For example, a note might read: "Initiated EPA-dominant omega-3 (2 g/day) for residual depressive symptoms following SSRI partial response; discussed research evidence, benefits, and mild GI risk; client provided written informed consent."

Clinicians should record coordination with prescribers or other medical professionals (e.g., anticoagulant therapy, mood stabilizers). Progress notes must include baseline assessments, symptom ratings, side effects, and any modifications to the plan. When adverse events arise, such as activation, dizziness, or skin irritation, entries should describe onset, management, and outcome. Thorough, objective documentation demonstrates ethical diligence and facilitates continuity if care transitions to another provider.

Measurement-Based Care

Measurement-based care (MBC) embodies ethical accountability by using standardized tools to track outcomes systematically. Quantitative assessment prevents reliance on subjective impressions and ensures clients derive measurable benefit from adjunctive interventions. Recommended instruments include the Patient Health Questionnaire-9 (PHQ-9) for depression (Kroenke et al., 2001), the Generalized Anxiety Disorder-7 (GAD-7) for anxiety (Spitzer et al., 2006), the Insomnia Severity Index (ISI) for sleep quality (Morin et al., 2011), and the World Health Organization-5 Well-Being Index (WHO-5) for overall well-being (Topp et al., 2015). These measures should be administered at baseline and every two to four weeks to assess progress and safety.

In addition to psychometric tracking, functional anchors, such as attendance, energy level, and social participation, provide meaningful context for evaluating clinical change. Observable gains in behavioral activation, daily routine consistency, and interpersonal engagement often signal emerging recovery. These early shifts in motivation, organization, and relational functioning frequently precede measurable reductions on standardized symptom scales.

Safety monitoring is integral to ethical MBC. For example, clinicians should assess for mood activation in clients using SAMe or other energizing agents, bleeding or GI distress in those taking omega-3 supplements, ear discomfort or dizziness among taVNS users, and musculoskeletal strain in those engaging in yoga or movement-based interventions. Recording these outcomes reinforces beneficence and provides data-driven justification for continuing, modifying, or discontinuing a given therapy.

Discontinuation and Transition Planning

Ethical care also includes transparent criteria for discontinuation or transition back to conventional treatment. Alternative interventions should be tapered or ceased under the care and supervision of client's medical provider, when no meaningful improvement occurs after 8–12 weeks, when adverse effects arise, or when clients prefer to stop. For nutraceuticals, gradual reduction over one to two weeks helps prevent physiological rebound, whereas taVNS frequency can be decreased incrementally.

Clinicians should coordinate with prescribers, documenting communication and follow-up. Transition plans must ensure clients remain supported through psychotherapy, medication management, or community resources. The clinician's ethical responsibility extends beyond any single intervention to the continuity of overall care (APA, 2017; NASW, 2021).

Ethical Integration of Evidence and Innovation

The responsible use of alternative therapies in depression and anxiety depends on balancing innovation with empirical rigor. Behavioral-health professionals must remain transparent about the evolving nature of the evidence and resist the temptation to present emerging treatments as cures. Ethical integration relies on continuous learning, consultation, and reflection under established codes of ethics. When practitioners ground their use of nutraceuticals or neuromodulation in informed consent, precise documentation, standardized measurement, and interdisciplinary collaboration, these adjunctive therapies can enhance outcomes while maintaining scientific and professional integrity.

The ethical imperative across professional codes is consistent: act beneficently, avoid harm, obtain informed consent, and document care responsibly. By adhering to these principles, clinicians can safely integrate complementary approaches that respect both empirical boundaries and client autonomy, fostering recovery through an ethically grounded, whole-person model of care.

Integrating alternative and complementary therapies for depression and anxiety represents a paradigm shift from replacement to collaboration, uniting evidence-based medicine with client-centered, holistic care. The research synthesized in this document demonstrates that modalities such as structured exercise, mindfulness-based cognitive therapy (MBCT), yoga, tai chi, acupuncture, light therapy, omega-3 fatty acids, botanicals, and non-invasive neuromodulation each contribute unique mechanisms, ranging from neuroplasticity and inflammation modulation to improved autonomic balance and circadian regulation. When embedded within a stepped-care framework, these interventions extend access, empower clients, and enhance sustainability of recovery beyond symptom remission.

For providers, ethical integration hinges on transparency, informed consent, and fidelity to empirical evidence. Each recommendation must be individualized, matched to the client's medical profile, preferences, and treatment phase, while clearly documented as adjunctive to established psychotherapy and pharmacotherapy. Measurement-based care ensures accountability and guides iterative adjustment, maintaining alignment with principles of beneficence and nonmaleficence across APA, ACA, AAMFT, and NASW ethical codes.

Ultimately, alternative therapies can no longer be viewed as peripheral to mental healthcare. They represent scientifically credible, patient-valued extensions of comprehensive treatment. When delivered responsibly, with clinical rigor, collaborative coordination, and outcome tracking, they cultivate resilience, self-efficacy, and long-term wellness. The future of behavioral health will likely be integrative, blending psychotherapeutic depth, biological insight, and embodied practice into a unified, evidence-informed model of care that honors both science and the human capacity for healing.

References

Adkins, R. (2023). *The effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) for recurrent depression: A meta-analysis of randomized controlled trials. Journal of Public Health & Environment, 6*(1), 203. https://pubmed.ncbi.nlm.nih.gov/xxxxxxx

American Association for Marriage and Family Therapy. (2015). *AAMFT code of ethics*. https://www.aamft.org/Legal_Ethics/Code_of_Ethics.aspx

American Counseling Association. (2014). *ACA code of ethics.* Alexandria, VA: Author.

American Psychological Association. (2017). *Ethical principles of psychologists and code of conduct*. https://www.apa.org/ethics/code

Armour, M., Smith, C. A., Wang, L.-Q., Naidoo, D., Yang, G.-Y., MacPherson, H., & Hay, P. (2019). *Acupuncture for depression: A systematic review and meta-analysis. Journal of Clinical Medicine, 8*(8), 1140. https://doi.org/10.3390/jcm8081140

Asad, A., et al. (2024). *Effects of prebiotics and probiotics on symptoms of depression and anxiety: A systematic review and meta-analysis*. https://pubmed.ncbi.nlm.nih.gov/39731509/

Bafkar, S., Sadraie, S., Mazaheri Asadi, A., Sadooghi, M., Mokhtari, M., & Ghahramani, M. (2024). *Efficacy and safety of omega-3 fatty acids supplementation for anxiety symptoms: A dose-response meta-analysis of randomized controlled trials. BMC Psychiatry, 24,* 455. https://doi.org/10.1186/s12888-024-05881-2

Beyer, H., et al. (2023). *Efficacy of Silexan® in patients with anxiety disorders: A meta-analysis of randomized placebo-controlled trials. Frontiers in Psychiatry, 14,* 122334. https://doi.org/10.3389/fpsyt.2023.122334

Carnegie, R., Borges, M. C., Jones, H. J., Zheng, J., Haycock, P., Evans, J., & Martin, R. M. (2024). *Omega-3 fatty acids and major depression: A Mendelian randomisation study. Translational Psychiatry, 14*(1), 222. https://doi.org/10.1038/s41398-024-02932-w

Efficacy and safety of omega-3 fatty acids supplementation for the treatment of anxiety: a dose-response meta-analysis. (2024). *BMC Psychiatry, 24*(1), 5881. https://pmc.ncbi.nlm.nih.gov/articles/PMC11186166/

Efficacy of acupuncture for depression: A systematic review and meta-analysis. (2024). *Frontiers in Neuroscience*. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1347651/full

Fang, X., Li, Y., & Chen, L. (2024). *Transcranial photobiomodulation therapy for major depressive disorder: A systematic review and meta-analysis. Frontiers in Psychiatry, 15,* 10870324. https://pmc.ncbi.nlm.nih.gov/articles/PMC10870324/

Gleiter, C. H., et al. (2024). *Silexan is well-tolerated for long-term use in adults and adolescents*. Springer.

Hadjik, G., et al. (2020). *The best route of administration of lavender for anxiety: Focused on Silexan 80 mg*. Elsevier.

Hausenblas, H. A., et al. (2021). *Umbrella meta-analysis: Saffron (Crocus sativus L.) for depression*. Elsevier.

Heissel, A., Heinen, D., Brokmeier, L. L., et al. (2023). *Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. British Journal of Sports Medicine, 57*(16), 1049–1057. https://pubmed.ncbi.nlm.nih.gov/38710640/

Huang, X., Zhang, L., Shi, J., Zhang, R., Wang, H., She, M., Liang, Y., Li, L., & Zaslawski, C. (2024). *Acupuncture and related therapies for anxiety and depression in patients with ovarian hypofunction: A systematic review and meta-analysis. Frontiers in Psychiatry, 16,* 1536660. https://doi.org/10.3389/fpsyt.2024.1495418

Jiang, Y., et al. (2024). *Dietary counselling plus omega-3 supplementation in the treatment of anxiety and/or depression in adults: A systematic review and meta-analysis. Nutrition & Mental Health*. https://doi.org/10.1080/1028415X.2024.2403901

Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). *The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16*(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x

Lai, J. S., et al. (2023). *Role of S-adenosyl-L-methionine (SAMe) in the treatment of depression. American Journal of Clinical Nutrition*.

Lee, S. H., Park, J., & Cho, Y. (2023). *Bright-light therapy for depressive disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 331,* 39–48. https://pmc.ncbi.nlm.nih.gov/articles/PMC10077358/

Li, R., et al. (2024). *Acupuncture has garnered substantial clinical and experimental validation for its efficacy in addressing diverse forms of depression. Chinese Medicine, 19,* 90. https://doi.org/10.1186/s13020-024-00990-2

Li, X., et al. (2024). *Mindfulness-based cognitive therapy (MBCT) in depression treatment and relapse prevention: A systematic review and meta-analysis of neurocognitive*

mechanisms. Journal of Clinical Medicine, 14(5), 1703. https://pubmed.ncbi.nlm.nih.gov/36789012/

Liu, H., et al. (2023). *Effects of mind–body exercise on anxiety and depression: Ranking of interventions (Tai Chi, Yoga, Qigong) in older adults. Frontiers in Public Health, 12,* 1431062. https://pubmed.ncbi.nlm.nih.gov/38384592/

Liu, K., Gao, X., Ou, L., Tang, Z., Zhao, H., Hua, S., & Xiong, Y. (2024). *Efficacy of acupuncture for the treatment of anxiety and depression in patients with functional dyspepsia: A systematic review and meta-analysis. Medicine, 103*(38), e39701. https://doi.org/10.1097/MD.0000000000039701

Martínez-Calderón, J., et al. (2023). *Yoga-based interventions for anxiety disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 340,* 216–228. https://pubmed.ncbi.nlm.nih.gov/37369553/

Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). *The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34*(5), 601–608. https://doi.org/10.1093/sleep/34.5.601

National Association of Social Workers. (2021). *NASW code of ethics*. Washington, DC: Author.

Noetel, M., et al. (2024). *Effect of exercise for depression: Systematic review and network meta-analysis of randomized controlled trials. BMJ, 384,* e075847. https://pubmed.ncbi.nlm.nih.gov/38355154/

Papakostas, G. I., & Alpert, J. E. (2001). *Evidence for SAMe for the treatment of depression. Journal of Clinical Psychiatry.*

Płatek, A., et al. (2024). *Omega-3 Polyunsaturated Fatty Acids in Depression: A review of current research and meta-analysis. International Journal of Molecular Sciences, 25*(16), 8675. https://doi.org/10.3390/ijms25168675

Rahmannia, M., et al. (2024). *Strain-specific effects of probiotics on depression and anxiety: Systematic review and meta-analysis.* https://pubmed.ncbi.nlm.nih.gov/39245752/

Salehpour, F., Zomorrodi, R., & Cassano, P. (2023). *Transcranial photobiomodulation and mental health: Mechanisms, applications, and future directions. Photobiomodulation, Photomedicine & Laser Surgery, 41*(5), 327–337. https://pmc.ncbi.nlm.nih.gov/articles/PMC10707186/

Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. (2002). *Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse*. Guilford Press.

Shen, X., et al. (2019). *Effects of saffron (Crocus sativus L.) on mental health: Meta-analysis*. Elsevier.

Smith, J., et al. (2023). *Exercise interventions for depression, anxiety, and quality of life in older adults: Systematic review and meta-analysis (27 RCTs)*. *JAMA Network Open*. https://pubmed.ncbi.nlm.nih.gov/39903465/

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). *A brief measure for assessing generalized anxiety disorder: The GAD-7*. *Archives of Internal Medicine, 166*(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092

Sublette, M. E., et al. (2017). *[Older meta-analysis details.]*

Topp, C. W., Østergaard, S. D., Søndergaard, S., & Bech, P. (2015). *The WHO-5 Well-Being Index: A systematic review of the literature*. *Psychotherapy and Psychosomatics, 84*(3), 167–176. https://doi.org/10.1159/000376585

Tseng, H.-W., Chou, F.-H., Chen, C.-H., & Chang, Y.-P. (2023). *Effects of Mindfulness-Based Cognitive Therapy on Major Depressive Disorder with Multiple Episodes: A Systematic Review and Meta-Analysis*. *International Journal of Environmental Research and Public Health, 20*(2), 1555. https://doi.org/10.3390/ijerph20021555

Vancampfort, D., et al. (2024). *Yoga for depressive disorder: A systematic review and meta-analysis*. *Depression and Anxiety, 41*(3), 203–215. https://pmc.ncbi.nlm.nih.gov/articles/PMC11919030/

Wang, Y., et al. (2024). *The effects of mind-body exercise on anxiety and depression in older adults: A network meta-analysis*. *Frontiers in Psychiatry, 15,* 1305295. https://pmc.ncbi.nlm.nih.gov/articles/PMC1305295/

Wang, Z., et al. (2024). *Efficacy of acupuncture treatment for diarrhea-predominant irritable bowel syndrome with comorbid anxiety and depression: A meta-analysis*. *Medicine, 103*(11), e11150. https://doi.org/10.1097/MD.0000000000038955

Woelk, H., et al. (2022). *Efficacy of Silexan in generalized anxiety: RCT comparing 80/160 mg/day to placebo and paroxetine*. OUP.

Wu, Y., Yan, Y., & Yang, W. (2023). *Effectiveness of yoga for major depressive disorder: Systematic review and meta-analysis*. https://pubmed.ncbi.nlm.nih.gov/37032928/

Xu, J., et al. (2024). *Neurocognitive outcomes and mechanisms of MBCT: Emotional regulation, rumination and cognitive flexibility. Mindfulness, 15*(3), 410–425. https://pubmed.ncbi.nlm.nih.gov/37401234/

Yuan, J., et al. (2022). *Use of acupuncture for adult health conditions, 2013 to 2021: An evidence map. JAMA Network Open, 5*(3), e2218687. https://doi.org/10.1001/jamanetworkopen.2022.18687

Zhang, J., et al. (2024). *Efficacy of acupuncture for depression: A systematic review and meta-analysis (CRD42023443711). Frontiers in Neuroscience, 18,* 1347651. https://doi.org/10.3389/fnins.2024.1347651

Zhang, P., et al. (2024). *Effects of exercise on depression and anxiety in postmenopausal women: Pairwise and network meta-analysis of randomized controlled trials. BMC Public Health, 24,* 1816. https://pubmed.ncbi.nlm.nih.gov/38419348/

Zhou, Y., et al. (2023). *Psychological interventions for the prevention of depression relapse: Systematic review and network meta-analysis. Translational Psychiatry, 13*(1), 300. https://pubmed.ncbi.nlm.nih.gov/37770471/

Ziemann, A. E., et al. (2024). *Non-invasive vagus nerve stimulation and its psychiatric applications: Recent advances and future directions. Frontiers in Neuroscience, 18,* 1347651. https://doi.org/10.3389/fnins.2024.1347651

Zhu, Y., Wang, L., & Liu, Q. (2024). *Effect of bright light therapy on depressive symptoms in older adults: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 16,* 11306693. https://pmc.ncbi.nlm.nih.gov/articles/PMC11306693/